Previous 10 | Next 10 |
The shares of I-Mab (NASDAQ:IMAB) are trading sharply lower in the morning hours Friday after the Chinese biotech announced early Phase 2 data for its CD73 antibody uliledlimab in combination with Coherus’ (CHRS) anti-PD1 therapy, toripalimab (TUOYI) in lung cancer. The updated data li...
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab PR Newswire - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity - Encouraging efficac...
Gainers: Splunk (SPLK) +5%. Core Scientific (CORZ) +5%. Change Healthcare (CHNG) +5%. Newmark Group (NMRK) +4%. Momentus (MNTS) +3%. Losers: Nutanix (NTNX) -27%. NVIDIA Corporation (NVDA) -7%. Datadog (DDOG) -6%. ViaSat (VSAT) -5%. I-MAB (IMAB) -5%. For further details...
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab PR Newswire SHANGHAI and GAITHERSBURG, MD . , May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage bioph...
There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result. The U.S.-China dispute element was in the headlines this week, when I-Mab’s name was added to a U.S. Securities an...
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act PR Newswire SHANGHAI and GAITHERSBURG, Md. , May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company commi...
I-Mab (NASDAQ:IMAB) announced the appointments of Mr. Richard Yeh as COO and Dr. John Hayslip as Chief Medical Officer. An industry veteran with 25+ years of experience spanning senior leadership positions with biopharmaceutical companies, Mr. Yeh will ...
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer PR Newswire - Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as ...
Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15% and Alabama Graphite Products break ground on Kellyton processing plant. IceCure Medical (...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...